TrialSignal
Clinical trial intelligence report
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01587898
Status
COMPLETED
Phase
Phase IIa
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The study evaluated GSK1278863, a prolyl hydroxylase inhibitor, for treating anemia in patients with chronic kidney disease not on dialysis. Conducted by GlaxoSmithKline, the trial involved 72 participants and aimed to assess safety, efficacy, and pharmacokinetics over four weeks.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01587898
Indication
Anaemia
Modality
small molecule
Target
Anemia associated with Chronic Kidney Disease
Intervention
GSK1278863, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.